uniQure price to sales ratio QURE

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: 83.3×
9-year median: 24.4×
Against its 9-year history: 78th; percentile: 0 is its lowest day, 100 its highest
9-year range: 1.2× to 199×
Peer median: 2.0×

uniQure's price to sales ratio is 83.3× as of Oct 23, 2026.

That is above its 9-year median of 24.4×, higher than on 78% of days in the last 9 years.

Over that time it ranged from 1.2× in May 2022 to 199× in Mar 2019.

The median for 10 large drugmakers of a similar size is 2.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	83.3×	55.4×	181×
2025	98.1×	17.8×	118×
2024	29.8×	2.3×	29.8×
2023	2.9×	2.4×	17.6×
2022	17.3×	1.2×	20.5×
2021	1.9×	1.9×	43.8×
2020	n/m a value too high to mean anything
2019	194×	85.6×	199×
2018	81.9×	27.6×	139×
2017	30.7×	23.6×	30.7×

Against its peers

Companies in Drug Manufacturers - General nearest uniQure's size, closest first, today.

Company	Price to sales ratio
QUREuniQure	83.3×
PAHCPhibro Animal Health	1.0×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
ANIPANI Pharmaceuticals	1.7×
OMEROmeros	n/m
HRMYHarmony Biosciences	2.2×
AMPHAmphastar Pharmaceuticals	1.5×
PBHPrestige Consumer Healthcare	2.0×
NRIXNurix Therapeutics	3.9×
ABUSArbutus Biopharma	4.6×
Peer median	2.0×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on uniQure

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.